Sam pictured with Brazilian legend Ronaldinho—widely regarded as one of the greatest footballers of all time—at the FIF ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company ...

The approval of ALYFTREK, our fifth CFTR modulator regimen, represents another significant milestone in that journey for people with CF in the UK," said Carmen Bozic, M.D., Executive Vice ...

NHS England’s latest offer comes less than a week after Vertex CEO Jeff Leiden wrote to UK Prime Minister Theresa May to express his disappointment about his company’s offer had been rejected.

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be on the road to a new era of growth. Alyftrek has surpassed Trikafta, Vertex ...

After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement over access to several cystic fibrosis treatments, capping an end to a long-running ...

On March 7, 2025, Vertex Pharmaceuticals announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its ...

The UK list price for the therapy stands at 1.65 million pounds ($2.09 million), a spokesperson for Vertex said, adding that the company cannot comment on a negotiated price. Britain's medical ...

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical ...